
Shane Leigh Jackson

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9701832/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Provision of a comprehensive medicines review is associated with lower mortality risk for residents of aged care facilities: a retrospective cohort study. Age and Ageing, 2022, 51, .	1.6	7
2	Does rural and urban community pharmacy practice differ? A narrative systematic review. International Journal of Pharmacy Practice, 2020, 28, 3-12.	0.6	15
3	Protecting the Herd: Why Pharmacists Matter in Mass Vaccination. Pharmacy (Basel, Switzerland), 2020, 8, 199.	1.6	23
4	Updating and validating quality prescribing indicators for use in Australian general practice. Australian Journal of Primary Health, 2020, 26, 31.	0.9	1
5	Coronial findings pertaining to nonâ€opioid and nonâ€benzodiazepine drugâ€related deaths in Australia. Journal of Pharmacy Practice and Research, 2019, 49, 257-261.	0.8	0
6	The Case For. Journal of Pharmacy Practice and Research, 2019, 49, 81-83.	0.8	0
7	Editorial: My Health Record: a community pharmacy perspective. Australian Prescriber, 2019, 42, 46.	1.0	11
8	Practice pharmacists and the opportunity to support general practitioners in deprescribing in the older person. Journal of Pharmacy Practice and Research, 2018, 48, 183-185.	0.8	8
9	Intervention fidelity for a complex behaviour change intervention in community pharmacy addressing cardiovascular disease risk. Health Education Research, 2015, 30, cyv050.	1.9	8
10	Describing drivers of and barriers to persistence with tiotropium in patients with chronic obstructive pulmonary disease: a mixed-methods approach. International Journal of Pharmacy Practice, 2015, 23, 154-157.	0.6	5
11	Advanced practice: a survey of current perspectives of Australian pharmacists. Journal of Pharmacy Practice and Research, 2015, 45, 186-192.	0.8	6
12	An Advanced Pharmacy Practice Framework for Australia. Pharmacy (Basel, Switzerland), 2015, 3, 13-26.	1.6	12
13	A multifaceted pharmacist intervention to improve antihypertensive adherence: a cluster-randomized, controlled trial (HAPPy trial). Journal of Clinical Pharmacy and Therapeutics, 2014, 39, 527-534.	1.5	79
14	Improving the management of warfarin in aged-care facilities utilising innovative technology: a proof-of-concept study. International Journal of Pharmacy Practice, 2014, 22, 84-91.	0.6	6
15	Uptake and effectiveness of a community pharmacy intervention programme to improve asthma management. Journal of Clinical Pharmacy and Therapeutics, 2013, 38, 212-218.	1.5	26
16	Supervised Patient Self-Testing of Warfarin Therapy Using an Online System. Journal of Medical Internet Research, 2013, 15, e138.	4.3	20
17	A Pilot Study Evaluating Multiple Risk Factor Interventions by Community Pharmacists to Prevent Cardiovascular Disease: The PAART CVD Pilot Project. Annals of Pharmacotherapy, 2012, 46, 183-191.	1.9	20
18	Vitamin B12 deficiency in Australian residential aged care facilities. Journal of Nutrition, Health and Aging, 2012, 16, 277-280.	3.3	17

SHANE LEIGH JACKSON

#	Article	IF	CITATIONS
19	Warfarin management after discharge from hospital: a qualitative analysis. Journal of Clinical Pharmacy and Therapeutics, 2012, 37, 410-414.	1.5	5
20	Utilizing community pharmacy dispensing records to disclose errors in hospital admission drug charts. International Journal of Clinical Pharmacology and Therapeutics, 2012, 50, 639-646.	0.6	18
21	Clinical Outcomes of a Collaborative, Home-Based Postdischarge Warfarin Management Service. Annals of Pharmacotherapy, 2011, 45, 325-334.	1.9	42
22	A 12-month follow-up study of "RedUSe― a trial aimed at reducing antipsychotic and benzodiazepine use in nursing homes. International Psychogeriatrics, 2011, 23, 1260-1269.	1.0	39
23	Stroke risk assessment for atrial fibrillation: hospital-based stroke risk assessment and intervention program. Journal of Clinical Pharmacy and Therapeutics, 2011, 36, 71-79.	1.5	9
24	The sustainability of a community pharmacy intervention to improve the quality use of asthma medication. Journal of Clinical Pharmacy and Therapeutics, 2011, 36, 144-151.	1.5	16
25	Perceived feasibility of a community pharmacy-based asthma intervention: a qualitative follow-up study. Journal of Clinical Pharmacy and Therapeutics, 2011, 36, 348-355.	1.5	19
26	Violence in community pharmacy in Australia: incidence and implications. International Journal of Clinical Pharmacy, 2011, 33, 264-272.	2.1	7
27	A role for pharmacists in community-based post-discharge warfarin management: protocol for the 'the role of community pharmacy in post hospital management of patients initiated on warfarin' study. BMC Health Services Research, 2011, 11, 16.	2.2	8
28	Drug-Related Problems Detected in Australian Community Pharmacies: The PROMISe Trial. Annals of Pharmacotherapy, 2011, 45, 1067-1076.	1.9	35
29	An effective approach to decrease antipsychotic and benzodiazepine use in nursing homes: the RedUSe project. International Psychogeriatrics, 2010, 22, 26-36.	1.0	78
30	Cardiovascular risk screening program in Australian community pharmacies. International Journal of Clinical Pharmacy, 2010, 32, 373-380.	1.4	49
31	Training Australian pharmacists for participation in a collaborative, home-based post-discharge warfarin management service. International Journal of Clinical Pharmacy, 2010, 32, 637-642.	1.4	8
32	Engaging community pharmacists in the primary prevention of cardiovascular disease: protocol for the Pharmacist Assessment of Adherence, Risk and Treatment in Cardiovascular Disease (PAART CVD) pilot study. BMC Health Services Research, 2010, 10, 264.	2.2	21
33	Evaluation of a community pharmacy-based intervention for improving patient adherence to antihypertensives: a randomised controlled trial. BMC Health Services Research, 2010, 10, 34.	2.2	27
34	Review of psychotropic medication in Tasmanian residential aged care facilities. Australasian Journal on Ageing, 2010, 29, 72-76.	0.9	9
35	Psycholeptic use in aged care homes in Tasmania, Australia. Journal of Clinical Pharmacy and Therapeutics, 2010, 35, 189-193.	1.5	21
36	Public perceptions of the role of Australian pharmacists in cardiovascular disease. Journal of Clinical Pharmacy and Therapeutics, 2010, 35, 671-677.	1.5	31

SHANE LEIGH JACKSON

#	Article	IF	CITATIONS
37	Who is responsible for the care of patients treated with warfarin therapy?. Medical Journal of Australia, 2009, 191, 575-577.	1.7	2
38	Drug-related problems identified in medication reviews by Australian pharmacists. International Journal of Clinical Pharmacy, 2009, 31, 216-223.	1.4	63
39	Attitudes of Australian pharmacists towards practice-based research. Journal of Clinical Pharmacy and Therapeutics, 2009, 34, 397-405.	1.5	57
40	Pharmacist-initiated general practitioner referral of patients with suboptimal asthma management. International Journal of Clinical Pharmacy, 2008, 30, 869-875.	1.4	33
41	Dataâ€mining of medication records to improve asthma management. Medical Journal of Australia, 2008, 189, 21-25.	1.7	68
42	Improving Clinical Outcomes for Hospital Patients Initiated on Warfarin. Journal of Pharmacy Practice and Research, 2007, 37, 295-302.	0.8	4
43	Development of an intelligent decision support system for medication review. Journal of Clinical Pharmacy and Therapeutics, 2007, 32, 81-88.	1.5	32
44	Harm minimization strategies: opinions of health professionals in rural and remote Australia. Journal of Clinical Pharmacy and Therapeutics, 2007, 32, 497-504.	1.5	16
45	The risks of warfarin use in the elderly. Expert Opinion on Drug Safety, 2006, 5, 417-431.	2.4	14
46	Antithrombotic treatment in atrial fibrillation. Expert Opinion on Drug Safety, 2006, 5, 597-597.	2.4	0
47	Accuracy and clinical utility of the CoaguChek XS portable international normalised ratio monitor in a pilot study of warfarin home-monitoring. Journal of Clinical Pathology, 2006, 60, 311-314.	2.0	65
48	Comment: Increased Sensitivity to Warfarin after Heart Valve Replacement. Annals of Pharmacotherapy, 2006, 40, 1476-1477.	1.9	2
49	Letters to the Editor: Discharge medication. Australian Prescriber, 2006, 29, 121.	1.0	1
50	Improving the outcomes of anticoagulation in rural Australia: an evaluation of pharmacist-assisted monitoring of warfarin therapy. Journal of Clinical Pharmacy and Therapeutics, 2005, 30, 345-353.	1.5	31
51	The direct thrombin inhibitor melagatran/ximelagatran. Medical Journal of Australia, 2005, 182, 254-255.	1.7	2
52	Closing the Gap between Evidence and Practice. Journal of Pharmacy Practice and Research, 2005, 35, 173-175.	0.8	0
53	Clopidogrel-aspirin combination for atrial fibrillation: CLAAF is not CLEAR. American Heart Journal, 2005, 149, E1.	2.7	1
54	A Community-Based Educational Intervention to Improve Antithrombotic Drug Use in Atrial Fibrillation. Annals of Pharmacotherapy, 2004, 38, 1794-1799.	1.9	37

SHANE LEIGH JACKSON

#	Article	IF	CITATIONS
55	Accuracy and clinical usefulness of the near-patient testing CoaguChek S international normalised ratio monitor in rural medical practice. Australian Journal of Rural Health, 2004, 12, 137-142.	1.5	23
56	Point-of-care monitoring of anticoagulant therapy by rural community pharmacists: Description of successful outcomes. Australian Journal of Rural Health, 2004, 12, 197-200.	1.5	12
57	Improving the outcomes of anticoagulation: an evaluation of home follow-up of warfarin initiation. Journal of Internal Medicine, 2004, 256, 137-144.	6.0	59
58	Accuracy, reproducibility and clinical utility of the CoaguChek S portable international normalized ratio monitor in an outpatient anticoagulation clinic. International Journal of Laboratory Hematology, 2004, 26, 49-55.	0.2	26
59	Randomized Trial of Warfarin Nomograms. Annals of Internal Medicine, 2004, 140, 488.	3.9	2
60	Suboptimal anticoagulant management in patients after hospital initiation of warfarin. Australian Family Physician, 2004, 33, 477-8.	0.5	5
61	Cost-effectiveness of Newer Antiplatelet Drugs. Archives of Internal Medicine, 2003, 163, 2533.	3.8	1
62	Doctors' beliefs on the use of antithrombotic therapy in atrial fibrillation: identifying barriers to stroke prevention. Internal Medicine Journal, 2002, 32, 15-23.	0.8	73
63	Outcomes in the management of atrial fibrillation: clinical trial results can apply in practice. Internal Medicine Journal, 2001, 31, 329-336.	0.8	56
64	Long term anticoagulation or antiplatelet treatment. BMJ: British Medical Journal, 2001, 323, 233-233.	2.3	5